Advice
Following a full submission.
Cilostazol (Pletal) is not recommended within NHS Scotland for the treatment of intermittent claudication.
It improves maximal and pain-free-walking distances more than placebo, but has limited effects on quality of life assessments. There are concerns about clinical effectiveness, including potential for several major drug interactions including with antiplatelet therapy which is recommended by the Scottish Intercollegiate Guidelines Network (SIGN) for patients with peripheral vascular disease. The economic case for this product has not been proven and it is substantially more expensive than its competitors.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Cilostazol (Pletal®)
- SMC ID:
- 86/04
- Indication:
- Maximal and pain-free walking distances in patients with intermittent claudication
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 February 2004